Overview

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

Status:
Completed
Trial end date:
2020-04-16
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the safety, tolerability, and therapeutic equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the efficacy of these two products to the GDC vehicle lotion (i.e., placebo) in the treatment of acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Gage Development Company, LLC
Treatments:
Clindamycin
Clindamycin palmitate
Clindamycin phosphate